Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: A retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort

Thrombosis Research

Volumn 133, Issue 5, 2014, Pages 772-781

  Matsushita, Tadashi ^a,h   Watanabe, Jyunichi ^b   Honda, Goichi ^b   Mimuro, Jun ^c,h   Takahashi, Hoyu ^d,h   Tsuji, Hajime ^e,h   Eguchi, Yutaka ^f,h   Kitajima, Isao ^g,h   Sakata, Yoichi ^c,h  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b ASAHI KASEI PHARMA CORPORATION   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d Niigata Prefectural Kamo Hospital   (Japan)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^f SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^g UNIVERSITY OF TOYAMA   (Japan)

^h Japan Soc on Thromb and Hemostasis Post Mktg Surveillance Committee for Recomodulin Injection   (Japan)

Author keywords

Acute promyelocytic leukemia; Disseminated intravascular coagulation; Recombinant human soluble thrombomodulin

Indexed keywords

RECOMBINANT PROTEIN; THBD PROTEIN, HUMAN; THROMBOMODULIN;

ADOLESCENT; ADULT; AGED; BLOOD; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMAN; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MULTICENTER STUDY; POSTMARKETING SURVEILLANCE; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COHORT STUDIES; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOMODULIN; YOUNG ADULT;

EID: 84898771788     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.02.025     Document Type: Article

References (50)

1. R. Ohno, N. Asou, and K. Ohnishi Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate Leukemia 17 2003 1454 1463
2. J.D. Rowley, H.M. Golomb, and C. Dougherty 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia Lancet 1 1977 549 550
3. F. Grignani, P.F. Ferrucci, U. Testa, G. Talamo, M. Fagioli, and M. Alcalay et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells Cell 74 1993 423 431
4. M.S. Tallman, and J.K. Altman How I treat acute promyelocytic leukemia Blood 114 2009 5126 5135
5. P. Fenaux, S. Castaigne, H. Dombret, E. Archimbaud, M. Duarte, and P. Morel et al. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases Blood 80 1992 2176 2181
6. T. Barbui, G. Finazzi, and A. Falanga The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia Blood 91 1998 3093 3102
7. E. Di Bona, G. Avvisati, G. Castaman, M. Luce Vegna, V. De Sanctis, and F. Rodeghiero et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia Br J Haematol 108 2000 689 695
8. P. Fenaux, M.C. Le Deley, S. Castaigne, E. Archimbaud, C. Chomienne, and H. Link et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group Blood 82 1993 3241 3249
9. M.S. Tallman, J.W. Andersen, C.A. Schiffer, F.R. Appelbaum, J.H. Feusner, and A. Ogden et al. All-trans-retinoic acid in acute promyelocytic leukemia N Engl J Med 337 1997 1021 1028
10. R.H. Jacomo, R.A. Melo, F.R. Souto, E.R. de Mattos, C.T. de Oliveira, and E.M. Fagundes et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines Haematologica 92 2007 1431 1432
11. S. Lehmann, A. Ravn, L. Carlsson, P. Antunovic, S. Deneberg, and L. Mollgard et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry Leukemia 25 2011 1128 1134
12. J.H. Park, B. Qiao, K.S. Panageas, M.J. Schymura, J.G. Jurcic, and T.L. Rosenblat et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid Blood 118 2011 1248 1254
13. T. Ito, and I. Maruyama Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation J Thromb Haemost 9 Suppl. 1 2011 168 173
14. H. Saito, I. Maruyama, S. Shimazaki, Y. Yamamoto, N. Aikawa, and R. Ohno et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial J Thromb Haemost 5 2007 31 41
15. T. Ikezoe, A. Takeuchi, M. Isaka, Y. Arakawa, N. Iwabu, and T. Kin et al. Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation Leuk Res 36 2012 1398 1402
16. M. Shindo, K. Ikuta, L. Addo, S. Ito, M. Fujiya, and Y. Torimoto et al. Successful control of disseminated intravascular coagulation by recombinant thrombomodulin during arsenic trioxide treatment in relapsed patient with acute promyelocytic leukemia Case Rep Hematol 2012 2012 908196
17. N. Kawano, T. Kuriyama, S. Yoshida, K. Yamashita, H. Ochiai, and S. Nakazaki et al. Clinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institution Intern Med 52 2013 55 62
18. S. Ichikawa, T. Suzuki, J. Kimura, and H. Harigae Successful treatment of acute promyelocytic leukemia accompanied by serious subdural hematoma Intern Med 51 2012 2209 2212
19. J. Mimuro, H. Takahashi, I. Kitajima, H. Tsuji, Y. Eguchi, and T. Matsushita et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation Thromb Res 131 2013 436 443
20. H. Asakura, H. Takahashi, H. Tsuji, T. Matsushita, H. Ninomiya, and G. Honda et al. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - Safety and efficacy in 1,032 patients with hematologic malignancy Thromb Res 133 2014 364 370
21. Japanese Ministry of Health, Labour, and Welfare Good Post-marketing Study Practice http://www.jpma.or.jp/english/parj/pdf/2012-ch04.pdf [Accessed April 15, 2012]
22. Japanese Ministry of Education, Culture, Sports, Science and Technology; Japanese Ministry of Health, Labour and Welfare Ethical Guidelines for Epidemiological Research http://www.lifescience.mext.go.jp/files/pdf/n796-01.pdf [Accessed April 15, 2012]
23. M. Yanada, T. Matsushita, N. Asou, Y. Kishimoto, M. Tsuzuki, and Y. Maeda et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome Eur J Haematol 78 2007 213 219
24. N. Kobayashi, T. Maekawa, M. Takada, H. Tanaka, and H. Gonmori Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan Bibl Haematol 49 1983 265 275
25. R. Watanabe, M. Murata, N. Takayama, M. Tokuhira, M. Kizaki, and S. Okamoto et al. Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Keio Hematology-Oncology Cooperative Study Group (KHOCS) Thromb Haemost 77 1997 641 645
26. V. De Stefano, F. Sora, E. Rossi, P. Chiusolo, L. Laurenti, and L. Fianchi et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment J Thromb Haemost 3 2005 1985 1992
27. M.A. Sanz, and P. Montesinos Open issues on bleeding and thrombosis in acute promyelocytic leukemia Thromb Res 125 Suppl. 2 2010 S51 S54
28. J.S. McClellan, H.E. Kohrt, S. Coutre, J.R. Gotlib, R. Majeti, and A.A. Alizadeh et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia Haematologica 97 2012 133 136
29. J. de la Serna, P. Montesinos, E. Vellenga, C. Rayon, R. Parody, and A. Leon et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin Blood 111 2008 3395 3402
30. J. Imagawa, Y. Harada, T. Shimomura, H. Tanaka, Y. Okikawa, and H. Harada High early death rate in elderly patients with acute promyelocytic leukemia treated with all-trans retinoic acid combined chemotherapy Int J Hematol 98 2014 264 266
31. G.J. Ventura, J.P. Hester, T.L. Smith, and M.J. Keating Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction Am J Hematol 27 1988 34 37
32. N. Dally, R. Hoffman, N. Haddad, G. Sarig, J.M. Rowe, and B. Brenner Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients Thromb Res 116 2005 109 114
33. D.Y. Kim, J.H. Lee, J.H. Lee, S.D. Kim, S.N. Lim, and Y. Choi et al. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia Leuk Res 35 2011 152 158
34. M. Pagoni, M. Garofalaki, F. Panitsas, K. Manola, K. Psarra, and P. Economopoulos et al. Acute promyelocytic leukemia: an experience on 95 Greek patients treated in the all-trans-retinoic acid era Mediterr J Hematol Infect Dis 3 2011 e2011053
35. M. Breccia, R. Latagliata, L. Cannella, C. Minotti, G. Meloni, and F. Lo-Coco Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation Haematologica 95 2010 853 854
36. M. Mitrovic, N. Suvajdzic, A. Bogdanovic, N.K. Kurtovic, A. Sretenovic, and I. Elezovic International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥ 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia Med Oncol 30 2013 478
37. M.S. Tallman, P. Lefebvre, R.M. Baine, M. Shoji, I. Cohen, and D. Green et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia J Thromb Haemost 2 2004 1341 1350
38. A. Falanga, L. Iacoviello, V. Evangelista, D. Belotti, R. Consonni, and A. D'Orazio et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid Blood 86 1995 1072 1081
39. K.A. Breen, D. Grimwade, and B.J. Hunt The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia Br J Haematol 156 2012 24 36
40. C. Arbuthnot, and J.T. Wilde Haemostatic problems in acute promyelocytic leukaemia Blood Rev 20 2006 289 297
41. L.O. Mosnier, J.C. Meijers, and B.N. Bouma Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin Thromb Haemost 85 2001 5 11
42. J.H. Foley, K.U. Petersen, C.J. Rea, L. Harpell, S. Powell, and D. Lillicrap et al. Solulin increases clot stability in whole blood from humans and dogs with hemophilia Blood 119 2012 3622 3628
43. J.C. Meijers, E.J. Oudijk, L.O. Mosnier, R. Bos, B.N. Bouma, and H.K. Nieuwenhuis et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia Br J Haematol 108 2000 518 523
44. J.S. Menell, G.M. Cesarman, A.T. Jacovina, M.A. McLaughlin, E.A. Lev, and K.A. Hajjar Annexin II and bleeding in acute promyelocytic leukemia N Engl J Med 340 1999 994 1004
45. T. Ikezoe, J. Yang, C. Nishioka, M. Isaka, N. Iwabu, and M. Sakai et al. Thrombomodulin enhances the antifibrinolytic and antileukemic effects of all-trans retinoic acid in acute promyelocytic leukemia cells Exp Hematol 40 2012 457 465
46. M.S. Tallman, B. Brenner, L. Serna Jde, H. Dombret, A. Falanga, and H.C. Kwaan et al. Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom Leuk Res 29 2005 347 351
47. A.P. Neyrinck, K.D. Liu, J.P. Howard, and M.A. Matthay Protective mechanisms of activated protein C in severe inflammatory disorders Br J Pharmacol 158 2009 1034 1047
48. M. Delvaeye, M. Noris, A. De Vriese, C.T. Esmon, N.L. Esmon, and G. Ferrell et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome N Engl J Med 361 2009 345 357
49. C.S. Shi, G.Y. Shi, S.M. Hsiao, Y.C. Kao, K.L. Kuo, and C.Y. Ma et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response Blood 112 2008 3661 3670
50. K. Abeyama, D.M. Stern, Y. Ito, K. Kawahara, Y. Yoshimoto, and M. Tanaka et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism J Clin Invest 115 2005 1267 1274